Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
Methods This is a retrospective study. G-CSF was administered in the dose of 10 μg/kg subcutaneous as a single dose for 4 days. On day 5, peripheral blood stem cell (PBSC) apheresis was performed using Haemonetics MCS plus or COBE Spectra apheresis machine through a double-lumen central venous cathe...
Main Authors: | Sadik Husian, Preethi Jeyaraman, S. K. Gupta, Reeta Rai, Sangeeta Pathak, Nitin Dayal, Rahul Naithani |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2021-09-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1729446 |
Similar Items
-
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01) -
Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
by: Siw Johannesen, et al.
Published: (2018-11-01) -
The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
by: Adam F. Binder, et al.
Published: (2017-10-01) -
Comparative Analysis of Dyes Used in the Assessment of Filgrastim Products Specific Activity by Biological <i>in vitro</i> Methods
by: O. V. Golovinskaya, et al.
Published: (2020-09-01) -
Therapeutic potential of the hematopoietic growth factors.
by: Usha D, et al.
Published: (1994-10-01)